本报（chinatimes.net.cn）记者张斯文 于娜 北京报道 湖北均瑶大健康饮品股份有限公司（下称"均瑶健康"，股票代码：605388.SH）于近日发布2025年年度 业绩预告。公告显示，公司预计2025年年度实现归属于上市公司股东的净利润为-2.16亿元到-1.44亿 元。 （来源：公司公告） 据公告，与上年同期相比，均瑶健康归属于上市公司股东的净利润将减少1.15亿元到1.87亿元，同比减 少395.14%到642.71%。上年同期该指标为-2911.64万元。 同时，公司预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净利润为-2.33亿元到-1.55 亿元，与上年同期相比将减少9704.89万元到1.75亿元，同比减少167.33%到301.00%。上年同期该指标 为-5799.79万元。 公告披露，业绩变动主要受市场环境影响，公司表示报告期内消费环境持续承压，含乳饮料市场份额有 所缩减，下游客户需求不振，公司传统常温乳酸菌业务收入水平较去年同期减少。 目前，这家公司正面临着传统核心产品"味动力"增长失速与新业务投入产出不成正比的双重问题。 "味动力"是均瑶健康主打的一款乳酸菌产品 ...

Core Insights - The company plans to focus its beverage business on probiotics by 2026, developing new products that cater to consumer health needs, including functional probiotic drinks, low-temperature live probiotic drinks, juice-based probiotic drinks, and probiotic sparkling water [1] Group 1: Product Development - The new product lineup will gradually enhance the product matrix and channel construction, forming a collaborative capacity and product layout for both ambient and refrigerated products [1] - The company aims to accelerate the coverage of new products in the top 100 CVS channels nationwide by 2026, having already engaged deeply with several leading channels [1] Group 2: Channel Strategy - The company will prioritize solidifying partnerships with leading chain channels and gradually expand into other channels, leveraging the advantages of these top channels to boost confidence among distributors regarding new products [1] - The first phase of co-branded products has exceeded market expectations, and the company plans to focus on collaboration in 2026, with new SKUs centered around unique probiotic strains [1] Group 3: Production Capacity - The company plans to expand production capacity in line with business needs, considering the number of new production lines to be added [1]

Core Viewpoint - The core reason for the fluctuation in the profit baseline for 2025 is the decline in the main business of Weiyuan Health, which is the key variable affecting the overall performance for the year [2] Summary by Categories Profit and Loss - The company anticipates that the decline in its main business will significantly impact its annual performance in 2025 [2] Impairment Provisions - Specific impairment provisions for 2025 include: - Accounts receivable and inventory impairments due to increased credit risk of certain receivables and decreased value of collateral [2] - Inventory impairment resulting from declining prices and extended turnover periods [2] - Goodwill impairment primarily related to the performance results of subsidiaries affected by industry conditions [2] - All impairments are based on a principle of prudence [2]

Core Insights - The company plans to focus on probiotic beverages as the core of its product strategy by 2026, aligning new product development with consumer health needs [2] - The product lineup will include functional probiotic drinks, low-temperature live probiotic drinks, juice-based probiotic drinks, and probiotic sparkling water, aiming to create a comprehensive product matrix and distribution network [2] Product and Channel Strategy - The company aims to enhance its offline channel presence, focusing on the recovery of existing products and the expansion of new product channels, with plans to accelerate new product coverage in the top 100 CVS channels by 2026 [2] - The company has already engaged with several leading channels and will prioritize collaboration with major chain channels before gradually expanding to other channels [2] - Leveraging the advantages of major channels will help boost confidence among distributors regarding new products, driving quality improvements and efficiency in the beverage business [2] Collaboration and Production Expansion - The initial market performance of co-branded products has exceeded expectations, prompting the company to focus on collaboration in 2026, with new SKUs centered around unique probiotic strains [2] - The company plans to launch these new products in March, coinciding with the beverage peak season, and will expand production capacity in line with business needs, considering the addition of new production lines [2]

Core Viewpoint - Junyao Health, known as the "first stock of ambient lactic acid bacteria" in A-shares, is facing significant financial challenges, with a projected net loss of between -216 million to -144 million yuan for 2025, marking a year-on-year decrease of 395.14% to 642.71% [2][15][25] Financial Performance - The company expects a substantial decline in net profit for 2025, with a projected loss of -233 million to -155 million yuan, representing a year-on-year decrease of 167.33% to 301.00% [2][15] - Since its listing in 2020, Junyao Health has experienced revenue growth, but net profit has consistently declined, showcasing a typical "increased revenue without increased profit" pattern, culminating in significant losses in 2025 [2][15][25] - Junyao Health's net profit has decreased for five consecutive years, with a reported revenue of 1.458 billion yuan in 2024, down 10.77% year-on-year, and a net profit of -29.12 million yuan, a decline of 150.57% [4][17] Factors Contributing to Losses - The anticipated losses for 2025 are attributed to several factors, including a challenging consumer environment leading to reduced market share in the dairy beverage sector, increased sales and marketing expenses, and higher research and development costs [4][17] - Significant impairment provisions for inventory and receivables, totaling an impact of 80 million to 140 million yuan, are identified as core drivers of the profit decline [4][17] - The company has previously reported substantial impairment losses, including 36.43 million yuan for goodwill and 12.76 million yuan for inventory write-downs in 2024, which have severely affected profitability [5][18] Market and Product Strategy - Junyao Health has attempted a "second entrepreneurship" strategy since 2021, focusing on upstream integration, new product launches, and diversification to mitigate reliance on single products [21] - Despite launching numerous new products since 2023, including those targeting specific consumer needs, the market response has been lukewarm, failing to generate significant sales volume or new growth points [10][23] - The company's marketing expenditures have surged, with sales expenses increasing by 30.27% to 245 million yuan in 2024 and a further 70.65% increase in the first half of 2025, which has further eroded profits [11][24] Stock Performance - Junyao Health's stock price has been on a downward trend since 2022, reaching a historical low of 4.18 yuan per share in 2024, and as of January 30, 2026, the stock price was 6.94 yuan, significantly lower than its initial offering price of 13.43 yuan [6][20] Future Outlook - Despite the current challenges, the dairy beverage industry still presents growth opportunities, with trends towards functionality, premiumization, and diversification [25][26] - Junyao Health possesses advantages in strain research and development, brand accumulation, and channel distribution, which could support a turnaround if strategic adjustments are made [25] - The company needs to focus on core business strengths, optimize product structure, and enhance cost control to gradually reverse the declining performance trend [25][26]

Core Insights - The mergers and acquisitions (M&A) in the Chinese food industry in 2025 are characterized by a focus on necessary integrations rather than large-scale deals, reflecting a shift towards survival in a saturated market [1] Group 1: Snack Industry Developments - Wanchen Group has transformed from a grassroots brand into a significant capital player, acquiring 49% of Nanjing Wanyou for 1.379 billion yuan, which is crucial for its brand integration strategy [2][3] - Nanjing Wanyou, under the "Good Idea" brand, generated 4.1 billion yuan in revenue in the first five months of 2025, highlighting its importance in Wanchen's portfolio [2] - The rapid expansion strategy of Wanchen has slowed significantly, with daily store openings dropping from 26 to less than 7, indicating market saturation and operational challenges [4] Group 2: Dairy Industry Trends - New Hope Dairy's acquisition of Fuzhou Aoni has taken six years to finalize, reflecting a cautious approach in a changing dairy market [7][9] - The acquisition is seen as a strategic move to solidify New Hope's presence in the southern market, but the company has shifted its focus from aggressive acquisitions to more sustainable growth strategies [9] - Junyao Health has adopted a different strategy by acquiring Runying Biotechnology, focusing on probiotic products, which saw a 60% revenue increase in the first three quarters of 2025 [9][10] Group 3: New Tea Beverage Sector - Mixue Ice City has made headlines by acquiring a 53% stake in the craft beer brand "Xianpi Fulu Jia" for nearly 300 million yuan, aiming to create a "day tea, night beer" business model [11][13] - The acquisition has faced criticism for its high premium, but the company leverages its extensive cold chain logistics to address the challenges of craft beer distribution [11] - In contrast, Heytea has paused its expansion plans, reflecting the industry's struggle with over-saturation and declining profitability [13] Group 4: Condiment Industry Challenges - Fuling Mustard's attempt to acquire Sichuan Weizimei has failed due to valuation disagreements, highlighting the difficulties traditional food companies face in finding growth opportunities [14][16] - The condiment industry is experiencing stagnation, with Fuling Mustard holding significant cash but struggling to identify viable growth avenues [16] - Industry leader Haitian Flavoring has opted for a Hong Kong listing to enhance its international presence and repair its reputation following regulatory challenges [16] Group 5: Overall Industry Trends - The 2025 M&A wave in the Chinese food and beverage sector reflects a broader theme of disillusionment, with consumers prioritizing value over brand prestige [17] - Companies are increasingly focusing on cost efficiency and profitability, as evidenced by Wanchen's and New Hope's strategic shifts [17] - The industry is moving towards consolidation, with larger firms dominating the market and employing data-driven strategies to optimize costs across the supply chain [17][18]

Summary of Conference Call Notes Company and Industry Overview - **Company**: Wei Dong Li (味动力) and Jun Yao Health (君药健康) - **Industry**: Probiotics and Beverage Industry Key Points and Arguments Wei Dong Li's Performance and Strategy - **Revenue Decline**: Wei Dong Li expects a double-digit revenue decline in 2025 due to the impact of snack retail channels [2][3] - **New Product Launches**: The company has introduced new products in the second half of 2025, which have entered some KA channels and are expected to drive beverage business growth [2][3] - **Probiotics Revenue**: Probiotics business is projected to generate approximately 100 million yuan in 2025, with expectations to reach 300 million yuan in 2026 after capacity expansion [2][3] - **C-end Business Growth**: The C-end business, Meizhu Doctor, has seen growth through partnerships with Hema and online-offline sales, aiming to expand revenue and product categories while maintaining profitability [2][3] - **Supply Chain Transition**: In 2026, the company plans to shift its supply chain to an internal team focused on selling proprietary products to improve gross margins [2][4] Collaboration with Hema - **Product Development**: The company has collaborated with Hema to launch four SKUs, including Qingmei Water and two types of coconut water, with Hema responsible for sales and the company for production [2][6] - **Sales Expectations**: This collaboration is expected to bring positive changes in Q4 and lay the foundation for beverage business growth in 2026 [2][6] Revenue and Capacity Projections - **Run Ying's Capacity**: Run Ying is expected to operate at full capacity in 2025, generating around 200 million yuan, falling short of the 600 million yuan target due to delayed expansion plans [2][3][7] - **Future Capacity**: If new capacity is successfully launched in 2026, revenue could reach approximately 300 million yuan, contributing an additional 100 million yuan [2][7] Profitability and Market Position - **Profit Margins**: Run Ying's net profit margin is currently low, with expectations of improvement as revenue increases to 300 million yuan [2][10] - **Competitive Advantages**: Run Ying is an A-level supplier for Danone, achieving 80% of the technical parameters of major overseas manufacturers while pricing at 60% of their cost, indicating a competitive edge [2][11] Market Dynamics and Challenges - **Market Competition**: The probiotics market faces intense competition, particularly in the domestic market, where price wars are prevalent due to oversupply [2][12] - **Raw Material Prices**: Current low prices for raw materials are expected to rise, with inflationary pressures anticipated in the consumer goods sector [2][15] Future Outlook - **New Product Expectations**: The company plans to continue developing new beverages in collaboration with Hema and other top-tier channels, which will be crucial for growth in 2026 [2][7][14] - **C-end Market Strategy**: The focus will be on high-quality profit generation rather than rapid growth, with a cautious approach to expanding into broader market segments [2][17] Financial Goals - **Daily Doctor's Revenue Goals**: Daily Doctor aims to exceed 200 million yuan in revenue in 2025, with plans to start beverage operations in 2026 [2][16] - **Profitability Challenges**: Achieving a 5%-10% profit margin remains challenging due to high costs associated with online sales and marketing [2][18] Customer Base Expansion - **International Market Focus**: Daily Doctor is actively expanding its customer base in Europe and the US, with a current monthly order volume of 20-30 million yuan [2][19] Additional Important Insights - **Product Quality Focus**: The company emphasizes quality and technological innovation to gain pricing power rather than engaging in price wars [2][12][13] - **Operational Efficiency**: There is a need for improved operational efficiency to meet customer demands and enhance profitability [2][11]

Core Insights - Junyao Health is experiencing ongoing performance challenges during its transformation, with a decline in both revenue and net profit reported for Q3 2025 [1][2] - The company has faced a continuous drop in net profit for five consecutive years, with a reported loss of 29.12 million yuan last year [1][2] - Despite a significant increase in revenue from probiotic products, overall revenue has decreased, and the company continues to invest heavily in sales, marketing, and R&D, making it difficult to alleviate performance declines in the short term [1][3] Financial Performance - For the first three quarters of 2025, Junyao Health reported approximately 1.095 billion yuan in revenue, a year-on-year decrease of 6.95% [2] - The net profit attributable to shareholders was a loss of approximately 2.3688 million yuan, a year-on-year decline of 104.79% [2] - In Q3 alone, revenue was about 329 million yuan, down 21.9% year-on-year, with a net profit loss of approximately 9.8349 million yuan, a decline of 167.09% [2] Business Challenges - The decline in performance is attributed to reduced income and increased expenditures, leading to a decrease in total profit from the beginning of the year to the reporting period [3] - Revenue from probiotic beverages decreased by 21.35% year-on-year to 386 million yuan, with declines observed across all major regions [3] - The company faces pressure from a challenging consumer environment, a shrinking market share in the dairy beverage sector, and weak downstream customer demand [3] Strategic Initiatives - Junyao Health is focusing on optimizing its revenue structure, with new product lines showing rapid development, although this has led to increased upfront sales and marketing costs [3][5] - The company has expanded its functional strain resource library to over 50,000 strains and successfully developed low-temperature probiotic beverages [3][5] - The overseas business has seen a significant growth of 72.20% compared to the same period last year, with products now available in over 80 countries and regions [3] Market Trends - The domestic beverage market is facing challenges due to the rapid growth of freshly made tea drinks, which are replacing standardized products like dairy and probiotic beverages [4] - The decline in the probiotic beverage market is also linked to changing consumer health preferences and the fragmentation of distribution channels [4] - The international market presents a key growth opportunity for Junyao Health, particularly for probiotic beverages, although rapid growth does not guarantee profitability [4] Product Development - Junyao Health has launched new probiotic products, including low-temperature active probiotic beverages, which are positioned to enhance overall profit margins [6][7] - The company aims to leverage its probiotic business to support future beverage operations, although challenges such as high cold chain costs and inventory management remain [6][7]

Core Insights - The article discusses the challenges faced by Junyao Health as consumer preferences shift towards low-sugar, additive-free, and functional products, leading to a decline in the sales of its flagship product, Weidongli [1][2][3] Group 1: Company Background and Historical Performance - Junyao Health was established in the 20th century, initially gaining popularity through policy benefits and advertising, and later transitioned to the health-focused yogurt market in 2004 [1] - The company launched Weidongli in 2011, which became a significant revenue driver, selling 5 billion bottles from 2014 to 2021 and contributing to its listing as the "first stock of ambient yogurt" [1][4] - However, the company has faced declining sales, with Weidongli's revenue dropping from 11.2 billion in 2017 to 7.54 billion in 2021, and a significant decline in yogurt sales from 2020 to 2023 [7][8] Group 2: Market Challenges and Consumer Trends - The high sugar content of yogurt products has led to a negative perception among health-conscious consumers, resulting in a shift away from traditional yogurt drinks [6][10] - The overall market for dairy beverages has contracted, with a nearly 13% decrease in market share reported in the second quarter of 2025 [8] - Junyao Health's attempts to innovate and expand its product lines have not yet yielded significant market acceptance, as evidenced by the lack of separate revenue reporting for Weidongli in recent financial statements [9][10] Group 3: Financial Performance and Strategic Shifts - In the first half of 2025, Junyao Health reported a revenue of 766 million, a year-on-year increase of 1.38%, but a net profit decline of 78.52% to 7.47 million [2] - The company has increased its marketing expenses significantly, with a 70.65% rise in sales and marketing costs, indicating a struggle to maintain profitability amid rising costs [10] - Despite the challenges in the yogurt segment, Junyao Health is pivoting towards the probiotic market, which has shown substantial growth potential, with an expected market size of 137.7 billion by 2026 [11][12] Group 4: Future Strategies and Market Positioning - Junyao Health aims to leverage its extensive strain library and partnerships with top universities to enhance its probiotic offerings, although it faces stiff competition from established international brands [13][16] - The company is focusing on both B2B and B2C strategies, aiming to provide customized services to dairy and health product companies while also targeting consumer health segments through innovative marketing [19] - The success of Junyao Health's future strategies hinges on effective consumer education and differentiation in a crowded market, as well as the establishment of a strong brand identity around its proprietary strains [18][19]

Core Viewpoint - The increasing awareness of health among consumers has led to a rapid growth in health-related consumption demands, with probiotics emerging as a popular choice for maintaining health and enhancing life quality [1]. Company Overview - Junyao Health, originally founded as Junyao Dairy in 1994, has evolved from promoting milk to focusing on probiotics, launching its first ambient lactic acid bacteria product in 2011 and becoming the first publicly listed company in the ambient lactic acid bacteria sector in 2020 [2][5]. Industry Innovation - In 2021, Junyao Health initiated a "second entrepreneurship" strategy, concentrating on innovation across the entire probiotic industry chain, including the acquisition of leading probiotic raw material producer Runying Bio to enhance its R&D and supply chain [4][6]. Quality Standards - Junyao Health has established the "Six Diamond Probiotic" standard to ensure the safety, stability, reliability, and effectiveness of its products, aiming to set a benchmark for the industry [6][7]. Research and Development - The company has developed over 4,000 proprietary functional probiotic strains and has established strategic partnerships with various domestic and international research institutions to enhance its R&D capabilities [6][8]. Clinical Validation - Junyao Health conducts rigorous clinical trials to validate the efficacy of its probiotics, such as the study demonstrating the benefits of its strains on oral health, showing significant reductions in inflammatory factors [11][13]. Product Development - The company has introduced various health solutions targeting gastrointestinal health, immune regulation, oral health, and more, under its sub-brands, creating a comprehensive product matrix to meet diverse consumer needs [15][18]. Long-term Commitment - Junyao Health emphasizes a long-term commitment to consumer health, advocating for a scientific approach to probiotic consumption and aiming to build lasting relationships with consumers [16][18].